Biotechnology
T-NanoBio Therapeutics, Inc. is a new emerging biotechnology company developing an innovative therapeutic platform based on transformable peptide nanoparticles. The technology consists of bispecific peptides that self-assemble, targeting tumor cells and cytotoxic T-cells, which result in a potent anti-tumor response in multiple oncology indications. Their nano immuno-engager (“NIE”) platform can harness a patient’s own immune system against cancer, while the HER2+ platform will offer a new treatment paradigm for treating HER2+ tumors. Both platforms offer a new dimension of therapeutic treatment as a potential cure for cancer.